<unk>  is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's<unk> " designation is not intended to imply that a drug is actually a<unk> " or that there is high-quality evidence of treatment efficacy for a particular condition; rather, it allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. The FDA has other mechanisms for expediting the review and approval process for promising drugs, including fast track designation, accelerated approval, and priority review.
Breakthrough therapy
Salvage therapy
Aversion therapy
Metronomic therapy
Combination therapy
Directed therapy
Dose-dense chemotherapy
Differentiation therapy